Cetera Investment Advisers Abb Vie Inc. Transaction History

Cetera Investment Advisers

$41.3 Billion
Q1 2024

A detailed history of Cetera Investment Advisers transactions in Abb Vie Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 608,224 shares of ABBV stock, worth $99.7 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

608,224

Previous 100,813 503.32%

Holding current value

$99.7 Million

Previous $18.4 Million 503.32%

% of portfolio

0.27%

Previous 0.2%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 24, 2024	BUY	$159.82 - $182.1 $81.1 Million - $92.4 Million	507,411 Added 503.32%	608,224 $111 Million
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $14.2 Million - $16.2 Million	-88,871 Reduced 46.85%	100,813 $18.4 Million
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $258,137 - $290,723	1,876 Added 1.0%	189,684 $29.4 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $360,025 - $416,781	2,695 Added 1.46%	187,808 $28 Million
Q2 2023 Aug 09, 2023	SELL	$132.51 - $164.9 $1.4 Million - $1.74 Million	-10,548 Reduced 5.39%	185,113 $24.9 Million

Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $464,198 - $534,593	-3,210 Reduced 1.61%	195,661 $31.2 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $9.36 Million - $11.2 Million	67,691 Added 51.6%	198,871 $32.2 Million
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $2.79 Million - $3.19 Million	-20,752 Reduced 13.66%	131,180 $17.6 Million
Q2 2022 Aug 11, 2022	SELL	$137.62 - $174.96 $2.49 Million - $3.17 Million	-18,123 Reduced 10.66%	151,932 $23.3 Million
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $421,676 - $523,181	3,195 Added 1.91%	170,055 $27.6 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $1.53 Million - $1.93 Million	14,200 Added 9.3%	166,860 $22.6 Million
Q3 2021 Nov 16, 2021	SELL	$106.4 - $120.78 $40,006 - $45,413	-376 Reduced 0.25%	152,660 $16.5 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $2.71 Million - $3.02 Million	25,794 Added 20.27%	153,036 $17.2 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $1.4 Million - $1.54 Million	-13,713 Reduced 9.73%	127,242 $13.8 Million
Q4 2020 Feb 17, 2021	BUY	$80.49 - $108.67 $9.02 Million - $12.2 Million	112,087 Added 388.27%	140,955 $15.1 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $250,857 - $294,423	2,920 Added 11.25%	28,868 $2.53 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $400,893 - $536,455	5,464 Added 26.67%	25,948 $2.55 Million
Q1 2020 May 08, 2020	SELL	$64.5 - $97.79 $240,391 - $364,463	-3,727 Reduced 15.39%	20,484 $1.56 Million
Q4 2019 Feb 10, 2020	SELL	$72.13 - $90.25 $94,634 - $118,408	-1,312 Reduced 5.14%	24,211 $2.15 Million
Q3 2019 Nov 06, 2019	SELL	$62.98 - $75.72 $6,990 - $8,404	-111 Reduced 0.43%	25,523 $1.94 Million
Q2 2019 Aug 12, 2019	SELL	$65.7 - $83.98 $40,668 - $51,983	-619 Reduced 2.36%	25,634 $1.86 Million
Q1 2019 May 06, 2019	BUY	$77.14 - $90.79 $106,838 - $125,744	1,385 Added 5.57%	26,253 $2.11 Million
Q4 2018 Feb 15, 2019	BUY	$77.85 - $96.01 $21,720 - $26,786	279 Added 1.13%	24,868 $2.3 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $511,321 - $568,428	-5,751 Reduced 18.96%	24,589 $2.33 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $42,825 - $50,671	477 Added 1.6%	30,340 $2.81 Million
Q1 2018 May 09, 2018	SELL	$92.01 - $123.21 $324,243 - $434,192	-3,524 Reduced 10.56%	29,863 $2.83 Million
Q4 2017 Feb 08, 2018	BUY	$89.56 - $98.21 $48,989 - $53,720	547 Added 1.67%	33,387 $3.24 Million
Q3 2017 Nov 16, 2017	SELL	$69.85 - $89.22 $42,818 - $54,691	-613 Reduced 1.83%	32,840 $2.91 Million
Q2 2017 Aug 17, 2017	SELL	N/A	-19,491 Reduced 36.81%	33,453 $2.43 Million
Q2 2017 Aug 14, 2017	BUY	N/A	52,944	52,944 $3.85 Million

Others Institutions Holding ABBV

# of Institutions

3,653

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $290B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.

Account

Cetera Investment Advisers Abb Vie Inc. Transaction History